No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > Breast Cancer Treatment

| More

BRCA & HBOC
Toggle Menu

Breast Cancer Treatment

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

Hereditary metastatic breast cancer

People with hereditary metastatic breast cancer have treatment options and special considerations that are different from people with non-hereditary, or earlier stage cancer. 

  • PARP inhibitors for metastatic breast cancer: Lynparza and Talzenna belong to a category of cancer treatment known as PARP inhibitors. Lynparza and Talzenna are currently FDA approved for use in metastatic breast cancer caused by a BRCA mutation. The National Comprehensive Cancer Network (NCCN) added Lynparza to their breast cancer treatment guidelines as a preferred single agent treatment for people with Her2-negativemetastatic breast cancer who carry a BRCA1 or BRCA2 mutation. You can read more about PARP inhibitors here
  • Participation in treatment clinical trials: Some research studies are exploring new treatments to specifically to treat hereditary metastatic breast cancer. Using our Research Search Tool, you can find clinical trials enrolling patients with hereditary metastatic breast cancer. 

  • Choice of chemotherapy: The Triple-Negative Breast Cancer Trial (TNT) compared the platinum-based drug carboplatin to the drug docetaxel as first line treatment in 376 patients with metastatic triple-negative breast cancer and/or with a mutation in BRCA1 or BRCA2. (Patients with BRCA mutations and ER/PR-positive breast cancer also were included in this study.) When researchers compared the two drugs in all patients, the response rate was similar for the two chemotherapies. However, when they examined the results for the 43 patients who had mutations in either BRCA1 or BRCA2, they found that 68.0% of carriers responded to carboplatin as compared with 33.3% of carriers who received docetaxel. The results of this study show the benefit of BRCA testing patients with advanced triple negative breast cancer. Those who test positive for a BRCA mutation may benefit from carboplatin over docetaxel.

Updated 10/25/2018

FORCE:Facing Our Risk of Cancer Empowered